A first-in-human phase 1 study of simnotrelvir, a 3CL-like protease inhibitor for treatment of COVID-19, in healthy adult subjects

Safe and efficacious antiviral therapeutics are in urgent need for the treatment of coronavirus disease 2019. Simnotrelvir is a selective 3C-like protease inhibitor that can effectively inhibit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We evaluated the safety, tolerability, and p...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	European journal of pharmaceutical sciences 2023-12, Vol.191, p.106598-106598, Article 106598
Hauptverfasser:	Yang, Xin-Mei, Yang, Yang, Yao, Bu-Fan, Ye, Pan-Pan, Xu, Yan, Peng, Shao-Ping, Yang, Yu-Mei, Shu, Pan, Li, Pei-Jin, Li, Shan, Hu, Hong-Lin, Li, Qian, Song, Lin-Lin, Chen, Ke-Guang, Zhou, Hai-Yan, Zhang, Ye-Hui, Zhao, Fu-Rong, Tang, Bo-Hao, Zhang, Wei, Zhang, Xin-Fang, Fu, Shu-Meng, Hao, Guo-Xiang, Zheng, Yi, Shen, Jing-Shan, Xu, Ye-Chun, Jiang, Xiang-Rui, Zhang, Lei-Ke, Tang, Ren-Hong, Zhao, Wei
Format:	Artikel
Sprache:	eng
Schlagworte:	COVID-19 Healthy subjects Pharmacokinetics Safety Simnotrelvir
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!